Drugs /

177lu-j591

Back to Drugs List

Overview

NCI Definition [1]:
A radioimmunoconjugate consisting of a humanized monoclonal antibody directed against the extracellular domain of prostate-specific membrane antigen linked to a beta-emitting radioisotope (lutetium-177). This radioimmunoconjugate binds to tumor cells that express the extracellular domain of prostate-specific membrane antigen, delivering beta particle radiation selectively to tumor cells expressing this antigen and so limiting the exposure of normal tissues to ionizing radiation.

Clinical Trials

View Clinical Trials for 177lu-j591

177lu-j591 has been investigated in 3 clinical trials, of which 2 are open and 1 is closed. Of the trials investigating 177lu-j591, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open).

Prostate adenocarcinoma and malignant solid tumor are the most common diseases being investigated in 177lu-j591 clinical trials [2].

Drug Details

Synonyms [2]:
lutetium lu 177 monoclonal antibody j591, lu 177 moab j591
Drug Target(s) [2]:
FOLH1
NCIT ID [1]:
C38701

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.